Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.58 |
| ▸ | GABRD | O14764 | 2/20 | 0.58 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.58 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.58 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.58 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.58 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.58 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.58 |
| ▸ | GABRE | P78334 | 2/20 | 0.58 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.58 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.58 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.58 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27908751 | 0.97 | GABRP (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL4886683 | 0.80 | ALDH1A1 (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3141529 | 0.79 | NNMT (0.58) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1867850 | 0.78 | MAP4K4 (0.57) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL1647572 | 0.77 | HDAC1 (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31497513 | 0.77 | HDAC1 (0.56) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL24051970 | 0.77 | HDAC6 (0.67) | HDAC1HDAC6HPGDNNMTSMN1; SMN2 | |
| SCHEMBL3705899 | 0.76 | ALDH1A1 (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL185448 | 0.76 | ALDH1A1 (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hydrochloric Acid SCHEMBL4040974 | 0.75 | HDAC1 (0.54) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 319 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085689-A1 | EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-24 | — | — | WO | claimed |
| CN-118993064-B | Green preparation method of carbon molecular sieve for screening and separating nitrogen and hydrogen | 广州广钢气体能源股份有限公司 | 2025-01-10 | — | — | CN | claimed |
| CN-118993064-A | Green preparation method of carbon molecular sieve for screening and separating nitrogen and hydrogen | 广州广钢气体能源股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| US-20240154124-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING SAME | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2024-05-09 | — | — | US | claimed |
| CN-116333411-B | Flame-retardant EVA (ethylene vinyl acetate) heat-insulating material and preparation method thereof | 石家庄启宏新材料制品有限公司 | 2023-08-11 | — | — | CN | claimed |
| CN-116333411-A | Flame-retardant EVA (ethylene vinyl acetate) heat-insulating material and preparation method thereof | 石家庄启宏新材料制品有限公司 | 2023-06-27 | — | — | CN | claimed |
| CN-108440769-B | Hydrogen-bonded porous copper coordination polymer and preparation method thereof | 同济大学 | 2021-03-26 | — | — | CN | claimed |
| CN-110655491-B | Simple preparation method of 2-aminopyrimidine-5-formic ether | 新发药业有限公司 | 2020-10-02 | — | — | CN | claimed |
| CN-108440769-A | A kind of porous copper coordination polymer and preparation method thereof of hydrogen bond connection | 同济大学 | 2018-08-24 | — | — | CN | claimed |
| CN-105130997-B | A kind of Ku Pannixi preparation method | 苏州明锐医药科技有限公司 | 2017-12-05 | — | — | CN | claimed |
| CN-105130998-B | Ku Pannixi preparation method | 苏州立新制药有限公司 | 2017-07-28 | — | — | CN | claimed |
| CN-105130997-A | Preparation method of copanlisib | SUZHOU MIRACPHARMA TECHNOLOGY CO LTD | 2015-12-09 | — | — | CN | claimed |
| CN-105130998-A | Preparation method for copanlisib | Suzhou lixin pharmaceutical co ltd | 2015-12-09 | — | — | CN | claimed |
| JP-4445553-B2 | — | — | 2010-04-07 | — | — | JP | claimed |
| US-7632591-B2 | Branched multiblock polybenzimidazole-benzamide copolymer and method for preparing the same, electrolyte membrane and paste/gel prepared therefrom | LG CHEM, LTD. (KR) | 2009-12-15 | — | — | US | claimed |
| JP-2008512561-A | — | — | 2008-04-24 | — | — | JP | claimed |
| WO-2007055459-A1 | BRANCHED MULTIBLOCK POLYBENZIMIDAZOLE-BENZAMIDE COPOLYMER AND METHOD FOR PREPARING THE SAME, ELECTROLYTE MEMBRANE AND PASTE/GEL PREPARED THEREFROM | LG CHEM, LTD. (KR) | 2007-05-18 | — | — | WO | claimed |
| US-20070111075-A1 | Branched multiblock polybenzimidazole-benzamide copolymer and method for preparing the same, electrolyte membrane and paste/gel prepared therefrom | LG CHEM, LTD. (KR) | 2007-05-17 | — | — | US | claimed |
| US-5006132-A | Membrane processed purified pipeline gas | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1991-04-09 | — | — | US | claimed |
| EP-4631941-A1 | BENZOTHIAZOLE PYRIMIDINEAMINE DYRK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | disclosed |
| US-12404269-B2 | Aminoquinazolinone and aminoisoquinolinone derivatives and application thereof | ZHEJIANG UNIVERSITY (CN) | 2025-09-02 | — | — | US | disclosed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025085689-A1 | EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-24 | — | — | WO | disclosed |
| US-12275707-B2 | Modulators of mas-related g-protein receptor X2 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| EP-4499632-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20250026735-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2025-01-23 | — | — | US | disclosed |
| CN-118993064-B | Green preparation method of carbon molecular sieve for screening and separating nitrogen and hydrogen | 广州广钢气体能源股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119095839-A | Quinoline derivatives as modulators and related products of Mas-associated G protein receptor X2 | 伊赛恩特制药公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-118146213-B | Benzothiazole pyrimidine amine DYRK2 inhibitor and preparation method and application thereof | 江苏天士力帝益药业有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-118993064-A | Green preparation method of carbon molecular sieve for screening and separating nitrogen and hydrogen | 广州广钢气体能源股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-12129243-B2 | Modulators of Mas-related G-protein receptor X2 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-12129244-B2 | Modulators of Mas-related G-protein receptor X2 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-20240336570-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2024-10-10 | — | — | US | disclosed |
| WO-2024119866-A1 | BENZOTHIAZOLE PYRIMIDINEAMINE DYRK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 江苏天士力帝益药业有限公司 | 2024-06-13 | — | — | WO | disclosed |
| CN-118146213-A | Benzothiazole pyrimidine amine DYRK2 inhibitor and preparation method and application thereof | 江苏天士力帝益药业有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118084892-A | Compounds useful as HPK1 inhibitors | 深圳福沃药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240154124-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING SAME | ZHUHAI COSMX BATTERY CO., LTD. (CN) | 2024-05-09 | — | — | US | disclosed |
| US-20240124415-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-04-18 | — | — | US | disclosed |
| US-20240124416-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-04-18 | — | — | US | disclosed |
| US-20240124414-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-04-18 | — | — | US | disclosed |
| US-11957683-B2 | Bicyclic compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| US-11919864-B2 | Modulators of Mas-related G-protein receptor X2 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20240059667-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-02-22 | — | — | US | disclosed |
| WO-2023192901-A9 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230399248-A1 | BACILLUS SP. SDC-U1 STRAIN WITH QUORUM QUENCHING ACTIVITY, COMPOSITION FOR INHIBITING BIOFILM INCLUDING THE SAME AND SYSTEM FOR TREATING WATER USING THE SAME FOR MEMBRANE BIOREACTOR | FOUNDATION FOR RESEARCH AND BUSINESS, SEOUL NATIONAL UNIVERSITY OF SCIENCE AND TECHNOLOGY (KR) | 2023-12-14 | — | — | US | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| CN-113851656-B | Negative electrode piece and lithium ion battery comprising same | 珠海冠宇电池股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-116333411-B | Flame-retardant EVA (ethylene vinyl acetate) heat-insulating material and preparation method thereof | 石家庄启宏新材料制品有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116333411-B | Flame-retardant EVA (ethylene vinyl acetate) heat-insulating material and preparation method thereof | 石家庄启宏新材料制品有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | disclosed |
| EP-4217345-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023139125-A1 | IMPROVED PROCESS FOR PREPARATION OF COPANLISIB | SYNTHON B.V. (NL) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139125-A1 | IMPROVED PROCESS FOR PREPARATION OF COPANLISIB | SYNTHON B.V. (NL) | 2023-07-27 | — | — | WO | disclosed |
| CN-116406357-A | Modulators of MAS-related G protein receptor X2 and related products and methods | 伊赛恩特制药公司 | 2023-07-07 | — | — | CN | disclosed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | disclosed |
| CN-116333411-A | Flame-retardant EVA (ethylene vinyl acetate) heat-insulating material and preparation method thereof | 石家庄启宏新材料制品有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116333411-A | Flame-retardant EVA (ethylene vinyl acetate) heat-insulating material and preparation method thereof | 石家庄启宏新材料制品有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2023046089-A1 | NEGATIVE ELECTRODE PLATE AND LITHIUM-ION BATTERY COMPRISING NEGATIVE ELECTRODE PLATE | 珠海冠宇电池股份有限公司 | 2023-03-30 | — | — | WO | disclosed |
| WO-2023046091-A1 | SOLID ELECTROLYTE AND USE THEREOF | 珠海冠宇电池股份有限公司 | 2023-03-30 | — | — | WO | disclosed |
| WO-2023046181-A1 | SOLID ELECTROLYTE AND LITHIUM ION BATTERY COMPRISING SAME | 珠海冠宇电池股份有限公司 | 2023-03-30 | — | — | WO | disclosed |
| CN-115724847-A | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives | 拜耳知识产权有限责任公司 | 2023-03-03 | — | — | CN | disclosed |
| US-20230065217-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230051483-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| EP-4132933-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-02-15 | — | — | EP | disclosed |
| WO-2022266193-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2022-12-22 | — | — | WO | disclosed |
| CN-101631464-B | 2,3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives for the treatment of hyperproliferative diseases and angiogenesis-related diseases | 拜耳知识产权有限责任公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-110475474-B | Compounds and methods of use | 西格纳姆生物科学公司 | 2022-11-04 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2638045-B1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER IP GMBH (DE) | 2022-08-31 | — | — | EP | disclosed |
| EP-2638045-B1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER IP GMBH (DE) | 2022-08-31 | — | — | EP | disclosed |
| CN-108774232-B | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives | 拜耳知识产权有限责任公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-109206580-B | Hybrid cross-linked dynamic polymer | 厦门天策材料科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| EP-3426657-B1 | 2 AMINO N [7 METHOXY 2, 3-DIHYDROIMIDAZO-[1, 2-C]QUINAZOLIN-5-YL]PYRIMIDINE 5 CARBOXAMIDES | Bayer Pharma AG (DE) | 2022-07-13 | — | — | EP | disclosed |
| CN-105254634-B | 2, 3-dihydroimidazo [1,2-c ] quinazoline substituted derivatives useful in the treatment of hyperproliferative diseases and angiogenesis-related diseases | 拜耳知识产权有限责任公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-108349960-B | Nostoc compounds and conjugates, their preparation and their therapeutic use | 赛诺菲 | 2022-05-27 | — | — | CN | disclosed |
| US-20220162186-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO | EMORY UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| WO-2022067094-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-20220017505-A1 | AMINOQUINAZOLINONE AND AMINOISOQUINOLINONE DERIVATIVES AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20220017505-A1 | AMINOQUINAZOLINONE AND AMINOISOQUINOLINONE DERIVATIVES AND APPLICATION THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2022-01-20 | — | — | US | disclosed |
| CN-113871699-A | Solid electrolyte and lithium ion battery comprising same | 珠海冠宇电池股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113871711-A | Negative pole piece and lithium ion battery comprising same | 珠海冠宇电池股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113871619-A | Positive plate and application thereof | 珠海冠宇电池股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113871708-A | Solid electrolyte and application thereof | 珠海冠宇电池股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113871709-A | Positive pole piece and solid-state battery comprising same | 珠海冠宇电池股份有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113851656-A | Negative pole piece and lithium ion battery comprising same | 珠海冠宇电池股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| CN-113851655-A | Negative pole piece and lithium ion battery comprising same | 珠海冠宇电池股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| EP-3904343-A1 | AMINO QUINAZOLINONE, AMINO ISOQUINOLONE DERIVATIVES AND APPLICATION THEREOF | Zhejiang University (CN) | 2021-11-03 | — | — | EP | disclosed |
| EP-3626713-B1 | CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| CN-108884098-B | 2-amino-N- [ 7-methoxy-2, 3-dihydroimidazo [1,2-c ] quinazolin-5-yl ] pyrimidine-5-carboxamides | 拜耳制药股份公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-107849044-B | Triaza-spirodecanones as DDR1 inhibitors | 豪夫迈·罗氏有限公司 | 2021-06-25 | — | — | CN | disclosed |
| US-20210163458-A1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2021-06-03 | — | — | US | disclosed |
| CN-108440769-B | Hydrogen-bonded porous copper coordination polymer and preparation method thereof | 同济大学 | 2021-03-26 | — | — | CN | disclosed |
| CN-108440769-B | Hydrogen-bonded porous copper coordination polymer and preparation method thereof | 同济大学 | 2021-03-26 | — | — | CN | disclosed |
| US-10941139-B2 | Cryptophycin compounds and conjugates, their preparation and their therapeutic use | SANOFI (FR) | 2021-03-09 | — | — | US | disclosed |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| CN-107074776-B | Synthesis of Copanlisib and its dihydrochloride | 拜耳制药股份公司 | 2021-02-02 | — | — | CN | disclosed |
| EP-3317279-B1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| CN-109516961-B | Aminoquinazolinone and aminoisoquinolinone derivatives and uses thereof | 浙江大学 | 2021-01-01 | — | — | CN | disclosed |
| WO-2020263960-A1 | COMPOSITIONS COMPRISING A RETINOID X RECEPTOR (RXR) AGONIST, A RETINOIC ACID RECEPTOR (RAR) AGONIST, OR A DUAL RXR/RAR AGONIST | WAGNER CARL (US) | 2020-12-30 | — | — | WO | disclosed |
| US-10844066-B2 | 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-11-24 | — | — | US | disclosed |
| US-10844066-B2 | 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-11-24 | — | — | US | disclosed |
| CN-108383849-B | Imidazoquinazoline derivative and application thereof in anti-tumor and anti-inflammation | 浙江大学 | 2020-11-06 | — | — | CN | disclosed |
| CN-110655491-B | Simple preparation method of 2-aminopyrimidine-5-formic ether | 新发药业有限公司 | 2020-10-02 | — | — | CN | disclosed |
| CN-110655491-B | Simple preparation method of 2-aminopyrimidine-5-formic ether | 新发药业有限公司 | 2020-10-02 | — | — | CN | disclosed |
| CN-111454188-A | Cyclopropylamines as L SD1inhibitors | 因赛特公司 | 2020-07-28 | — | — | CN | disclosed |
| US-10717737-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-07-21 | — | — | US | disclosed |
| WO-2020134921-A1 | AMINO QUINAZOLINONE, AMINO ISOQUINOLONE DERIVATIVES AND APPLICATION THEREOF | 浙江大学 | 2020-07-02 | — | — | WO | disclosed |
| WO-2020134921-A1 | AMINO QUINAZOLINONE, AMINO ISOQUINOLONE DERIVATIVES AND APPLICATION THEREOF | 浙江大学 | 2020-07-02 | — | — | WO | disclosed |
| CN-109467536-B | Synthesis method of 2-chloro/hydroxypyrimidine-5-carboxylic acid | 沧州普瑞东方科技有限公司 | 2020-06-05 | — | — | CN | disclosed |
| EP-3626713-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Incyte Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| CN-106164066-B | Cyclopropylamines as LSD1inhibitors | 因赛特公司 | 2020-01-17 | — | — | CN | disclosed |
| CN-110655491-A | Simple preparation method of 2-aminopyrimidine-5-formic ether | 新发药业有限公司 | 2020-01-07 | — | — | CN | disclosed |
| CN-110655491-A | Simple preparation method of 2-aminopyrimidine-5-formic ether | 新发药业有限公司 | 2020-01-07 | — | — | CN | disclosed |
| CN-107278204-B | Synthesis of Copanlisib and its dihydrochloride | 拜耳制药股份公司 | 2019-12-17 | — | — | CN | disclosed |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-10-08 | — | — | US | disclosed |
| EP-3105218-B1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORP (US) | 2019-09-25 | — | — | EP | disclosed |
| EP-3371179-B1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2019-08-07 | — | — | EP | disclosed |
| US-20190211014-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-07-11 | — | — | US | disclosed |
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-06-06 | — | — | US | disclosed |
| EP-3489232-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20190092775-A1 | 2-AMINO-N- [7-METHOXY-2, 3-DIHYDROIMIDAZO-[1, 2-C] QUINAZOLIN-5-YL] PYRIMIDINE-5-CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-28 | — | — | US | disclosed |
| US-20190092775-A1 | 2-AMINO-N- [7-METHOXY-2, 3-DIHYDROIMIDAZO-[1, 2-C] QUINAZOLIN-5-YL] PYRIMIDINE-5-CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-28 | — | — | US | disclosed |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2019-03-26 | — | — | US | disclosed |
| CN-109467536-A | 2- chlorine/hydroxy pyrimidine -5- carboxylic acid synthetic method | 沧州普瑞东方科技有限公司 | 2019-03-15 | — | — | CN | disclosed |
| CN-105294737-B | The compound and application thereof of CDK type small molecular inhibitor | 广东东阳光药业有限公司 | 2019-02-12 | — | — | CN | disclosed |
| EP-3215493-B1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | Bayer Pharma AG (DE) | 2019-01-23 | — | — | EP | disclosed |
| EP-3215493-B1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | Bayer Pharma AG (DE) | 2019-01-23 | — | — | EP | disclosed |
| EP-3426657-A1 | 2 AMINO N [7 METHOXY 2, 3-DIHYDROIMIDAZO-[1, 2-C]QUINAZOLIN-5-YL]PYRIMIDINE 5 CARBOXAMIDES | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-16 | — | — | EP | disclosed |
| US-10174030-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2019-01-08 | — | — | US | disclosed |
| EP-3215507-B1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | Bayer Pharma AG (DE) | 2018-12-26 | — | — | EP | disclosed |
| CN-108884098-A | 2- amino-N- [7- methoxyl group -2,3- glyoxalidine simultaneously [1,2-c] quinazoline -5- base] pyrimidine -5- benzamide type | 拜耳制药股份公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-108774232-A | 2,3- glyoxalidine simultaneously [1,2-c] quinazoline substitutive derivative | 拜耳知识产权有限责任公司 | 2018-11-09 | — | — | CN | disclosed |
| US-20180319772-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-11-08 | — | — | US | disclosed |
| US-10106526-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180282337-A1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-04 | — | — | US | disclosed |
| EP-3371179-A1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2018-09-12 | — | — | EP | disclosed |
| US-10059690-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2018-08-28 | — | — | US | disclosed |
| CN-108440769-A | A kind of porous copper coordination polymer and preparation method thereof of hydrogen bond connection | 同济大学 | 2018-08-24 | — | — | CN | disclosed |
| CN-108383849-A | Imidazoquinazoline derivatives and its it is antitumor it is anti-inflammatory in application | 浙江大学 | 2018-08-10 | — | — | CN | disclosed |
| CN-108349960-A | New nostoc element compound and conjugate, their preparation and their therapeutical uses | 赛诺菲 | 2018-07-31 | — | — | CN | disclosed |
| US-10035803-B2 | Synthesis of copanlisib and its dihydrochloride salt | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-31 | — | — | US | disclosed |
| US-10035803-B2 | Synthesis of copanlisib and its dihydrochloride salt | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-31 | — | — | US | disclosed |
| US-10035803-B2 | Synthesis of copanlisib and its dihydrochloride salt | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-31 | — | — | US | disclosed |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2018-07-26 | — | — | US | disclosed |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA-ROCHE INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-RE46856-E1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-05-22 | — | — | US | disclosed |
| US-RE46856-E1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-05-22 | — | — | US | disclosed |
| US-RE46856-E1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-05-22 | — | — | US | disclosed |
| EP-3317279-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-05-09 | — | — | EP | disclosed |
| US-9902727-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-9902727-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| US-9902727-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-C]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2018-02-27 | — | — | US | disclosed |
| CN-105130997-B | A kind of Ku Pannixi preparation method | 苏州明锐医药科技有限公司 | 2017-12-05 | — | — | CN | disclosed |
| US-20170342070-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-11-30 | — | — | US | disclosed |
| US-20170327505-A1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-16 | — | — | US | disclosed |
| US-20170327505-A1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-16 | — | — | US | disclosed |
| US-20170327505-A1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-16 | — | — | US | disclosed |
| CN-107278204-A | Copanlisib and its dihydrochloride synthesis | 拜耳制药股份公司 | 2017-10-20 | — | — | CN | disclosed |
| WO-2017153220-A1 | 2—AMINO—N— [7—METHOXY—2, 3-DIHYDROIMIDAZO-[1, 2-C] QUINAZOLIN-5-YL] PYRIMIDINE—5—CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153220-A1 | 2—AMINO—N— [7—METHOXY—2, 3-DIHYDROIMIDAZO-[1, 2-C] QUINAZOLIN-5-YL] PYRIMIDINE—5—CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-14 | — | — | WO | disclosed |
| EP-3215493-A2 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | Bayer Pharma Aktiengesellschaft (DE) | 2017-09-13 | — | — | EP | disclosed |
| EP-3215507-A1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | Bayer Pharma Aktiengesellschaft (DE) | 2017-09-13 | — | — | EP | disclosed |
| EP-2638044-B1 | ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER IP GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-2638044-B1 | ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER IP GMBH (DE) | 2017-08-30 | — | — | EP | disclosed |
| CN-107074776-A | Synthesis of Copanlisib and its Dihydrochloride | 拜耳制药股份公司 | 2017-08-18 | — | — | CN | disclosed |
| US-9730943-B2 | Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730943-B2 | Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| US-9730943-B2 | Alkoxy-substituted 2,3-dihydroimidazo[1,2-C]quinazolines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-08-15 | — | — | US | disclosed |
| CN-105130998-B | Ku Pannixi preparation method | 苏州立新制药有限公司 | 2017-07-28 | — | — | CN | disclosed |
| US-20170183355-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-29 | — | — | US | disclosed |
| US-9682953-B2 | Amide compounds, compositions and applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-06-20 | — | — | US | disclosed |
| US-9682953-B2 | Amide compounds, compositions and applications thereof | ADVINUS THERAPEUTICS LIMITED (IN) | 2017-06-20 | — | — | US | disclosed |
| US-9675616-B2 | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9675616-B2 | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| US-9675616-B2 | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-C]quinolines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2017-06-13 | — | — | US | disclosed |
| EP-2638043-B1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | BAYER IP GMBH (DE) | 2017-06-07 | — | — | EP | disclosed |
| EP-2638043-B1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | BAYER IP GMBH (DE) | 2017-06-07 | — | — | EP | disclosed |
| US-9670210-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2017076998-A1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2017-05-11 | — | — | WO | disclosed |
| US-20170107212-A1 | NOVEL COMPOUNDS | Bayer Pharma AG (DE) | 2017-04-20 | — | — | US | disclosed |
| CN-106458983-A | Novel compound | 拜耳制药股份公司 | 2017-02-22 | — | — | CN | disclosed |
| EP-3126352-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| EP-3119759-A1 | NOVEL COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2017-01-25 | — | — | EP | disclosed |
| WO-2017005583-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-01-12 | — | — | WO | disclosed |
| EP-3105218-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Incyte Corporation (US) | 2016-12-21 | — | — | EP | disclosed |
| CN-106164066-A | Cyclopropylamines as lsd1 inhibitors | 因赛特公司 | 2016-11-23 | — | — | CN | disclosed |
| CN-102906094-B | For treating hyperproliferative disorders and 2,3-glyoxalidine also [1,2-c] quinazoline derivant occurring the amino alcohol of relevant disease to replace to blood vessel | 拜耳知识产权有限责任公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-103339133-B | 2 of alkoxyl replacement, 3-glyoxalidine is [1,2-c] quinazoline also | 拜耳知识产权有限责任公司 | 2016-06-15 | — | — | CN | disclosed |
| WO-2016071426-A1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016071426-A1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016071435-A2 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| WO-2016071435-A2 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-05-12 | — | — | WO | disclosed |
| EP-3018127-A1 | Synthesis of copanlisib and its dihydrochloride salt | Bayer Pharma Aktiengesellschaft (DE) | 2016-05-11 | — | — | EP | disclosed |
| EP-3018127-A1 | Synthesis of copanlisib and its dihydrochloride salt | Bayer Pharma Aktiengesellschaft (DE) | 2016-05-11 | — | — | EP | disclosed |
| EP-3018131-A1 | Synthesis of copanlisib and its dihydrochloride salt | Bayer Pharma Aktiengesellschaft (DE) | 2016-05-11 | — | — | EP | disclosed |
| EP-3018131-A1 | Synthesis of copanlisib and its dihydrochloride salt | Bayer Pharma Aktiengesellschaft (DE) | 2016-05-11 | — | — | EP | disclosed |
| CN-103370320-B | 2,3-glyoxalidine also [1,2-c] quinoline that arylamino alcohol replaces | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-04-27 | — | — | CN | disclosed |
| EP-2096919-B1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER IP GMBH (DE) | 2016-03-02 | — | — | EP | disclosed |
| CN-105294737-A | Compound of CDK small-molecule inhibitor and application thereof | GUANGDONG HEC PHARMACEUTICAL | 2016-02-03 | — | — | CN | disclosed |
| CN-105254634-A | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORP | 2016-01-20 | — | — | CN | disclosed |
| CN-105130997-A | Preparation method of copanlisib | SUZHOU MIRACPHARMA TECHNOLOGY CO LTD | 2015-12-09 | — | — | CN | disclosed |
| CN-105130998-A | Preparation method for copanlisib | Suzhou lixin pharmaceutical co ltd | 2015-12-09 | — | — | CN | disclosed |
| WO-2015154039-A2 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015140195-A1 | NOVEL COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015123465-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-20 | — | — | WO | disclosed |
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| EP-2619197-B1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INT (DE) | 2015-08-05 | — | — | EP | disclosed |
| CN-102633728-B | Synthesis method of 2-amino-pyrimidyl-4,6-diformic acid | UNIV GUANGXI NORMAL | 2015-07-15 | — | — | CN | disclosed |
| US-20150125390-A1 | 18F-LABELLED FOLATE/ANTIFOLATE ANALOGUES | Merck & Cie (CH) | 2015-05-07 | — | — | US | disclosed |
| US-20150080374-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| US-20150080374-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| US-20150080374-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-19 | — | — | US | disclosed |
| US-8895549-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895549-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895549-B2 | Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8859572-B2 | Sulfone substituted 2,3-dihydroimidazo [1,2-C] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-10-14 | — | — | US | disclosed |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
| US-8822534-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| US-8822534-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| CN-102414177-B | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT | 2014-07-02 | — | — | CN | disclosed |
| EP-2149816-B1 | METHOD OF MANUFACTURING AN ELECTROCHROMIC DISPLAY ELEMENT | KONICA MINOLTA HOLDINGS INC (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-20140113896-A1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| US-20140113896-A1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| US-20140113896-A1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-24 | — | — | US | disclosed |
| US-20130330327-A1 | ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-12 | — | — | US | disclosed |
| US-20130317004-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-28 | — | — | US | disclosed |
| US-8575201-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| US-8575201-B2 | Oxadiazole inhibitors of leukotriene production | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-05 | — | — | US | disclosed |
| CN-103370320-A | Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines | BAYER IP GMBH | 2013-10-23 | — | — | CN | disclosed |
| US-20130261113-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION | 2013-10-03 | — | — | US | disclosed |
| US-20130261113-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION | 2013-10-03 | — | — | US | disclosed |
| US-20130261113-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION | 2013-10-03 | — | — | US | disclosed |
| CN-103339133-A | Alkoxy-substituted 2,3-dihydroimidazo[1,2-c]quinazolines | BAYER IP GMBH | 2013-10-02 | — | — | CN | disclosed |
| EP-2638043-A1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | Bayer Intellectual Property GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2638044-A1 | ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | Bayer Pharma Aktiengesellschaft (DE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2638045-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Intellectual Property GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| US-8466283-B2 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-8466283-B2 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-8466283-B2 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| EP-2401256-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2013-04-17 | — | — | EP | disclosed |
| WO-2013042139-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-03-28 | — | — | WO | disclosed |
| US-8394853-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| CN-102906094-A | Aminoalcohol substituted 2, 3-dihydroimidazo[1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | Bayer Pharma AG | 2013-01-30 | — | — | CN | disclosed |
| US-20120295896-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295896-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-11-22 | — | — | US | disclosed |
| EP-2508525-A1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts | Bayer Pharma Aktiengesellschaft (DE) | 2012-10-10 | — | — | EP | disclosed |
| CN-102633728-A | Synthesis method of 2-amino-pyrimidyl-4,6-diformic acid | UNIV GUANGXI NORMAL | 2012-08-15 | — | — | CN | disclosed |
| EP-1778388-B1 | MEMBRANE GAZ SEPERATION | TNO (NL) | 2012-06-06 | — | — | EP | disclosed |
| WO-2012062745-A1 | ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062748-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062743-A1 | ARYLAMINOALCOHOL-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINOLINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-18 | — | — | WO | disclosed |
| CN-102414177-A | Compounds as bradykinin b1 antagonists | BOEHRINGER INGELHEIM INT | 2012-04-11 | — | — | CN | disclosed |
| WO-2012040139-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-29 | — | — | WO | disclosed |
| EP-2401256-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| CN-101163696-B | Histone deacetylase inhibitors | CHROMA THERAPEUTICS LTD | 2011-09-14 | — | — | CN | disclosed |
| US-20110190281-A1 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-04 | — | — | US | disclosed |
| US-20110083984-A1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20110083984-A1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20110083984-A1 | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline Derivatives Useful for Treating Hyper-Proliferative Disorders and Diseases Associated with Angiogenesis | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-04-14 | — | — | US | disclosed |
| US-7888351-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-02-15 | — | — | US | disclosed |
| US-20110034462-A1 | ORGANIC COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2011-02-10 | — | — | US | disclosed |
| EP-2265615-A1 | IMIDAZOPYRIMIDINE, IMIDAZOPYRAZINE AND IMIDAZOPYRIDAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| EP-2244721-A2 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO Ý1,2-C¨QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | Bayer Schering Pharma AG (DE) | 2010-11-03 | — | — | EP | disclosed |
| US-20100267748-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010045371-A1 | PYRIDO- AND PYRIMIDO (1, 2-A) PYRIMIDINE COMPOUNDS USEFUL AS STEAROYL COA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010034500-A1 | SUBSTITUTED IMIDAZOPYRIDINE, IMIDAZOPYRAZINE, IMIDAZOPYRIDAZINE AND IMIDAZOPYRIMIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR ANTAGONISTS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| EP-2168965-A1 | Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-03-31 | — | — | EP | disclosed |
| CN-101631464-A | Substituted 2, 3-dihydroimidazo [1, 2-c ] quinazoline derivatives for the treatment of hyperproliferative and angiogenesis-related diseases | BAYER SCHERING PHARMA AG | 2010-01-20 | — | — | CN | disclosed |
| US-7632591-B2 | Branched multiblock polybenzimidazole-benzamide copolymer and method for preparing the same, electrolyte membrane and paste/gel prepared therefrom | LG CHEM, LTD. (KR) | 2009-12-15 | — | — | US | disclosed |
| US-20090281069-A1 | ORGANIC COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-11-12 | — | — | US | disclosed |
| WO-2009115321-A1 | MIDAZOPYRIMIDINE, IMIDAZOPYRAZINE AND IMIDAZOPYRIDAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| EP-2103614-A1 | Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| US-7591878-B2 | Separating CO2 from CO2-rich liquid comprising step in which under elevated pressure liquid is contacted with membrane based on polyacetylene substituted with trimethylsilyl groups, while pressure difference across membrane is at least 1 bar and while at least part of CO2 is transported through membrane | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2009-09-22 | — | — | US | disclosed |
| EP-2096919-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-09 | — | — | EP | disclosed |
| EP-1268443-B1 | 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 2009-07-29 | — | — | EP | disclosed |
| WO-2009091550-A2 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | BAYER HEALTHCARE LLC (US) | 2009-07-23 | — | — | WO | disclosed |
| EP-2007723-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2008133344-A2 | PIPERIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | WO | disclosed |
| US-20080275085-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-06 | — | — | US | disclosed |
| WO-2008070150-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070150-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-06-12 | — | — | WO | disclosed |
| CN-101163696-A | Histone deacetylase inhibitors | CHROMA THERAPEUTICS LTD (GB) | 2008-04-16 | — | — | CN | disclosed |
| WO-2007115821-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| US-20070214957-A1 | Separating CO2 from CO2-rich liquid comprising step in which under elevated pressure liquid is contacted with membrane based on polyacetylene substituted with trimethylsilyl groups, while pressure difference across membrane is at least 1 bar and while at least part of CO2 is transported through membrane | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2007-09-20 | — | — | US | disclosed |
| US-7259157-B2 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | MERCK & CO., INC. (US) | 2007-08-21 | — | — | US | disclosed |
| WO-2007055459-A1 | BRANCHED MULTIBLOCK POLYBENZIMIDAZOLE-BENZAMIDE COPOLYMER AND METHOD FOR PREPARING THE SAME, ELECTROLYTE MEMBRANE AND PASTE/GEL PREPARED THEREFROM | LG CHEM, LTD. (KR) | 2007-05-18 | — | — | WO | disclosed |
| US-20070111075-A1 | Branched multiblock polybenzimidazole-benzamide copolymer and method for preparing the same, electrolyte membrane and paste/gel prepared therefrom | LG CHEM, LTD. (KR) | 2007-05-17 | — | — | US | disclosed |
| EP-1778388-A1 | MEMBRANE GAZ SEPERATION | Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO (NL) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006004400-A1 | MEMBRANE GAZ SEPERATION | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2006-01-12 | — | — | WO | disclosed |
| US-6972297-B2 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-12-06 | — | — | US | disclosed |
| EP-1390034-A4 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO INC (US) | 2005-07-13 | — | — | EP | disclosed |
| CN-1210267-C | 2-hydroxy-mutilin carbamate derivatives for antibacterial use | SMITHKLINE BEECHAM PLC (GB) | 2005-07-13 | — | — | CN | disclosed |
| US-20040204341-A1 | Nr2b receptor antagonists for the treatment or prevention of migraines | ALLEN CHRISTOPHER (US) | 2004-10-14 | — | — | US | disclosed |
| EP-1399160-A4 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO INC (US) | 2004-08-25 | — | — | EP | disclosed |
| EP-1399160-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | Merck & Co., Inc. (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1390034-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | Merck & Co., Inc. (US) | 2004-02-25 | — | — | EP | disclosed |
| CN-1427827-A | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | SMITHKLINE BEECHAM PLC (GB) | 2003-07-02 | — | — | CN | disclosed |
| US-20030119811-A1 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | MERCK SHARP & DOHME CORP. | 2003-06-26 | — | — | US | disclosed |
| US-20030114674-A1 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-19 | — | — | US | disclosed |
| EP-1268443-A1 | 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE | SmithKline Beecham p.l.c. (GB) | 2003-01-02 | — | — | EP | disclosed |
| WO-2002100352-A2 | NR2B RECEPTOR ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF MIGRAINES | MERCK & CO., INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002080928-A1 | N-SUBSTITUTED NONARYL-HETEROCYCLO AMIDYL NMDA/NR2B ANTAGONISTS | MERCK & CO., INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001074788-A1 | 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 2001-10-11 | — | — | WO | disclosed |
| EP-0866708-A4 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0866708-A1 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-09-30 | — | — | EP | disclosed |
| US-5707423-A | Substituted polyacetylene separation membrane | MEMBRANE TECHNOLOGY AND RESEARCH, INC. (US) | 1998-01-13 | — | — | US | disclosed |
| WO-1997017969-A1 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-05-22 | — | — | WO | disclosed |
| US-5006132-A | Membrane processed purified pipeline gas | AIR PRODUCTS AND CHEMICALS, INC. (US) | 1991-04-09 | — | — | US | disclosed |
| EP-0325131-A2 | Pyrimidine derivatives as performance stimulating agents | BAYER AG (DE) | 1989-07-26 | — | — | EP | disclosed |
| US-4248618-A | Derivatives of (pyrimidyloxy)phenoxy-alkanecarboxylic acid and herbicidal compositions thereof | ICI AUSTRALIA LIMITED (AU) | 1981-02-03 | — | — | US | disclosed |
| US-4248618-A | Derivatives of (pyrimidyloxy)phenoxy-alkanecarboxylic acid and herbicidal compositions thereof | ICI AUSTRALIA LIMITED (AU) | 1981-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114674-A1 | 2-Hydroxy-mutilin carbamate derivatives for antibacterial use | MSH6, MSH2, PMS2 | GABRP 817/4885GABRD 595/4885GABRA1 1266/4885 |
| US-10035803-B2 | Synthesis of copanlisib and its dihydrochloride salt | COPS2, COPS6, COPS4 | GABRP 3502/4885GABRD 3826/4885GABRA1 4105/4885 |
| US-11919864-B2 | Modulators of Mas-related G-protein receptor X2 and related products and methods | MRGPRX2, MRGPRX1, MRGPRX4 | GABRP 306/4885GABRD 384/4885GABRA1 318/4885 |
| US-20130261113-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | PIK3CA, PIK3CD, PIK3CB | GABRP 2843/4885GABRD 4675/4885GABRA1 4707/4885 |
| US-20150125390-A1 | 18F-LABELLED FOLATE/ANTIFOLATE ANALOGUES | FOLR1, FOLR2, SLC19A1 | GABRP 1809/4885GABRD 2516/4885GABRA1 999/4885 |
| US-20210163458-A1 | NOVEL CRYPTOPHYCIN COMPOUNDS AND CONJUGATES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | XPOT, HCCS, COIL | GABRP 2647/4885GABRD 4464/4885GABRA1 3770/4885 |
| US-10059690-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | GABRP 4819/4885GABRD 4865/4885GABRA1 4690/4885 |
| US-20230065217-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | GABRP 306/4885GABRD 384/4885GABRA1 318/4885 |
| US-20170327505-A1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | COPS2, COPS6, COPS4 | GABRP 3502/4885GABRD 3826/4885GABRA1 4105/4885 |
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | GABRP 4435/4885GABRD 4468/4885GABRA1 3284/4885 |
| US-12275707-B2 | Modulators of mas-related g-protein receptor X2 and related products and methods | MRGPRX2, MRGPRX1, MRGPRX4 | GABRP 306/4885GABRD 384/4885GABRA1 318/4885 |
| US-10717737-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | GABRP 4435/4885GABRD 4468/4885GABRA1 3284/4885 |
| US-10106526-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | GABRP 4819/4885GABRD 4865/4885GABRA1 4690/4885 |
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | GABRP 4775/4885GABRD 3318/4885GABRA1 2872/4885 |
| US-20240124415-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | GABRP 330/4885GABRD 357/4885GABRA1 305/4885 |
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | GABRP 1895/4885GABRD 2639/4885GABRA1 1246/4885 |
| US-10941139-B2 | Cryptophycin compounds and conjugates, their preparation and their therapeutic use | XPOT, COIL, HCCS | GABRP 3023/4885GABRD 4494/4885GABRA1 3907/4885 |
| US-20230051483-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | GABRP 1479/4885GABRD 1781/4885GABRA1 701/4885 |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | GABRP 3780/4885GABRD 2265/4885GABRA1 2099/4885 |
| US-20180208578-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | GABRP 4819/4885GABRD 4865/4885GABRA1 4690/4885 |
| US-20130317004-A1 | AMINOALCOHOL SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | PIK3CA, PIK3CD, PIK3C2A | GABRP 2588/4885GABRD 4435/4885GABRA1 4445/4885 |
| US-20170342070-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | GABRP 4435/4885GABRD 4468/4885GABRA1 3284/4885 |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | GABRP 4775/4885GABRD 3318/4885GABRA1 2872/4885 |
| US-20190211014-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | GABRP 4435/4885GABRD 4468/4885GABRA1 3284/4885 |
| US-12404269-B2 | Aminoquinazolinone and aminoisoquinolinone derivatives and application thereof | PIK3R5, PIK3CA, PIK3R1 | GABRP 570/4885GABRD 1302/4885GABRA1 1336/4885 |
| US-10844066-B2 | 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides | PIK3CA, PIK3CD, PIK3CB | GABRP 1847/4885GABRD 4374/4885GABRA1 4204/4885 |
| US-20080275085-A1 | Piperidine derivative and use thereof | TACR2, TACR1, PRLHR | GABRP 519/4885GABRD 953/4885GABRA1 499/4885 |
| US-20170107212-A1 | NOVEL COMPOUNDS | WNT1, CTNNB1, WNT3A | GABRP 4859/4885GABRD 4773/4885GABRA1 4856/4885 |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | GABRP 4775/4885GABRD 3318/4885GABRA1 2872/4885 |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | GABRP 850/4885GABRD 3189/4885GABRA1 1128/4885 |
| US-20120295896-A1 | OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION | LTB4R, LTC4S, LTB4R2 | GABRP 3273/4885GABRD 2767/4885GABRA1 2417/4885 |
| US-20220162186-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, AND USES RELATED THERETO | PTGER2, PTGES2, PTGES | GABRP 524/4885GABRD 784/4885GABRA1 559/4885 |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | GABRP 850/4885GABRD 3189/4885GABRA1 1128/4885 |
| US-11957683-B2 | Bicyclic compounds | SLC10A1, PKD1, CYP11B2 | GABRP 1479/4885GABRD 1781/4885GABRA1 701/4885 |
| US-20220017505-A1 | AMINOQUINAZOLINONE AND AMINOISOQUINOLINONE DERIVATIVES AND APPLICATION THEREOF | PIK3R5, PIK3CA, PIK3R1 | GABRP 570/4885GABRD 1302/4885GABRA1 1336/4885 |
| US-12129244-B2 | Modulators of Mas-related G-protein receptor X2 and related products and methods | MRGPRX2, MRGPRX1, MRGPRX4 | GABRP 330/4885GABRD 357/4885GABRA1 305/4885 |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | GABRP 4435/4885GABRD 4468/4885GABRA1 3284/4885 |
| US-20250026735-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | GABRP 330/4885GABRD 357/4885GABRA1 305/4885 |
| US-20190092775-A1 | 2-AMINO-N- [7-METHOXY-2, 3-DIHYDROIMIDAZO-[1, 2-C] QUINAZOLIN-5-YL] PYRIMIDINE-5-CARBOXAMIDES | PIK3CA, PIK3CD, PIK3CB | GABRP 1847/4885GABRD 4374/4885GABRA1 4204/4885 |
| US-20180319772-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | GABRP 4819/4885GABRD 4865/4885GABRA1 4690/4885 |
| US-20240124416-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | GABRP 330/4885GABRD 357/4885GABRA1 305/4885 |
| US-20090281069-A1 | ORGANIC COMPOUNDS | OTC, OAT, SLCO2B1 | GABRP 2557/4885GABRD 3216/4885GABRA1 1927/4885 |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | GABRP 4775/4885GABRD 3318/4885GABRA1 2872/4885 |
| US-20180282337-A1 | SYNTHESIS OF COPANLISIB AND ITS DIHYDROCHLORIDE SALT | COPS2, COPS4, COPS6 | GABRP 4294/4885GABRD 4534/4885GABRA1 4499/4885 |
| US-20040204341-A1 | Nr2b receptor antagonists for the treatment or prevention of migraines | HTR1B, HTR2B, HTR1A | GABRP 291/4885GABRD 190/4885GABRA1 115/4885 |
| US-20130330327-A1 | ALKOXY-SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES | VEGFA, KDR, FLT1 | GABRP 4732/4885GABRD 4769/4885GABRA1 4637/4885 |
| US-20110190281-A1 | SULFONE SUBSTITUTED 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES WITH ANGIOGENESIS | PIK3CA, PIK3CD, PIK3CB | GABRP 2669/4885GABRD 4708/4885GABRA1 4677/4885 |
| US-20240336570-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | GABRP 306/4885GABRD 384/4885GABRA1 318/4885 |
| US-20240124414-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | GABRP 330/4885GABRD 357/4885GABRA1 305/4885 |
| US-20030119811-A1 | N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists | GRIN1, GRIN2B, GRIN2A | GABRP 59/4885GABRD 73/4885GABRA1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.